Smarter Cancer Care
Genomic Health delivers the promise and value of precision medicine
with the Oncotype IQ portfolio of genomic tests.

Landmark TAILORx Results

The long-awaited results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) definitively identified the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

What Is the Test

The Oncotype DX® test analyses the activity of 21 genes from the breast cancer tumour to provide an individual Recurrence Score® result, which is unique to the biology of a patient’s cancer.

Getting Tested

The Oncotype DX test should be used when the benefit of chemotherapy for a patient is uncertain. The test increases both the patient and her doctor’s confidence in treatment decisions.

An individual individual answer.

Visit these pages for further information on the Oncotype DX test, cancer-related terminology, and FAQs.

Contact Us

Get in Touch
Making cancer care smarter.™

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.